

<b>Clinical Policy Title:</b>	Sodium Oxybate solution
<b>Policy Number:</b>	RxA.804
<b>Drug(s) Applied:</b>	Sodium Oxybate (Amneal), Lumryz, Xyrem
<b>Original Policy Date:</b>	01/01/2024
<b>Last Review Date:</b>	01/01/2024
<b>Line of Business Policy Applies to:</b>	All lines of business (except Medicare)

**Criteria**

**I. Initial Approval Criteria**

**A. Cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.**(must meet all):

1. Trial and failure of Sodium Oxybate (Hikma), unless contraindicated or clinically significant adverse effects are experienced.

**Approval duration**

**All Lines of Business (except Medicare):** 12 months

**II. Continued Therapy Approval**

**All Indications in Section I** (must meet all):

1. Member is currently receiving medication, excluding manufacturer samples;

**Approval duration**

**All Lines of Business (except Medicare):** 12 months

**References**

1. Morgenthaler TI, Kapur VK, Brown T, et al. Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin an American Academy of Sleep Medicine Report: An American Academy of Sleep Medicine Report. Sleep. 2007; 30(12): 1705-1711. Available at: [https://aasm.org/resources/practiceparameters/pp\\_narcolepsy.pdf](https://aasm.org/resources/practiceparameters/pp_narcolepsy.pdf). Accessed December 08, 2023.
2. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF. Treatment of Narcolepsy and other Hypersomnias of Central Origin: An American Academy of Sleep Medicine Review. Sleep. 2007;30(12):1712-1727. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276130/>. Accessed December 08, 2023.
3. Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39-57. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344488/>. Accessed December 08, 2023.

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	1/2024	10/19/2023

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.